Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pharmacol Biochem Behav. 2010 Nov;97(1):130-7. doi: 10.1016/j.pbb.2010.05.009. Epub 2010 May 15.
Olanzapine is an antipsychotic drug that frequently induces weight gain accompanied by increased fat deposition as a side effect. To investigate how olanzapine affects different aspects of energy balance, we used male rats to determine effects on meal patterns, food preference, locomotor activity and body temperature. In two short-term experiments olanzapine was administered via osmotic minipumps. In the first experiment, we offered rats standard lab chow only. In the second experiment, we offered rats free choice between chow, sucrose and saturated fat. In a third experiment, olanzapine was chronically administered via the drinking water to determine effects on body composition. In each experiment olanzapine decreased locomotor activity and altered meal patterns. Olanzapine caused an increase in average meal size accompanied by reduced meal frequency, without clearly affecting food preference. In the chronic experiment body composition was altered, favoring adipose tissue over lean muscle mass, despite reductions in overall body weight gain. The increase in average meal size implies that the primary effect of olanzapine on feeding is an impairment of the normal satiation process. Furthermore, energy balance is clearly affected by a reduction in locomotor activity. Thus, the effects of olanzapine on adiposity do not depend solely on the presence of hyperphagia.
奥氮平是一种抗精神病药物，常因其副作用导致体重增加和脂肪沉积增加。为了研究奥氮平如何影响能量平衡的不同方面，我们使用雄性大鼠来确定其对摄食模式、食物偏好、运动活动和体温的影响。在两项短期实验中，奥氮平通过渗透微型泵给药。在第一个实验中，我们只给大鼠提供标准实验室饲料。在第二个实验中，我们在大鼠中提供了自由选择标准实验室饲料、蔗糖和饱和脂肪的机会。在第三个实验中，奥氮平通过饮用水进行慢性给药，以确定其对身体成分的影响。在每个实验中，奥氮平都降低了运动活动并改变了摄食模式。奥氮平导致平均餐量增加，同时减少了进食频率，但对食物偏好没有明显影响。在慢性实验中，身体成分发生了改变，脂肪组织相对于瘦肌肉质量增加，尽管总体体重增加减少。平均餐量的增加意味着奥氮平对摄食的主要影响是损害正常的饱腹感过程。此外，运动活动的减少明显影响能量平衡。因此，奥氮平对肥胖的影响并不完全依赖于暴食的存在。
